Immunotherapy with monoclonal antibodies in lung cancer of mice: oxidative stress and other biological events

Tang, Jun; Ramis Cabrer, Daniel, 1993-; Wang, Xuejie; Barreiro Portela, Esther

doi:http://dx.doi.org/10.3390/cancers11091301

Immunotherapy with monoclonal antibodies in lung cancer of mice: oxidative stress and other biological events

License

Citation

Tang J, Ramis-Cabrer D, Wang X, Barreiro E. Immunotherapy with monoclonal antibodies in lung cancer of mice: oxidative stress and other biological events. Cancers (Basel). 2019 Sep 4;11(9):1301. DOI: 10.3390/cancers11091301

Abstract

Background: Lung cancer (LC) is a major leading cause of death worldwide. Immunomodulators that target several immune mechanisms have proven to reduce tumor burden in experimental models through induction of the immune microenvironment. We hypothesized that other biological mechanisms may also favor tumor burden reduction in lung cancer-bearing mice treated with immunomodulators. Methods: Tumor weight, area, T cells and tumor growth (immunohistochemistry), oxidative stress, apoptosis, autophagy, and signaling (NF-κB and sirtuin-1) markers were analyzed (immunoblotting) in subcutaneous tumor of BALB/c mice injected with LP07 adenocarcinoma cells treated with monoclonal antibodies (CD-137, CTLA-4, PD-1, and CD-19, N = 9/group) and non-treated control animals. Results: Compared to non-treated cancer mice, in tumors of monoclonal-treated animals, tumor area and weight and ki-67 were significantly reduced, while T cell counts, oxidative stress, apoptosis, autophagy, activated p65, and sirtuin-1 markers were increased. Conclusions: Immunomodulators elicited a reduction in tumor burden (reduced tumor size and weight) through decreased tumor proliferation and increased oxidative stress, apoptosis, autophagy, and signaling markers, which may have interfered with the immune profile of the tumor microenvironment. Future research should be devoted to the elucidation of the specific contribution of each biological mechanism to the reduced tumor burden.